1026 Mirati KRAS data
BioCentury & Getty Images

Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

Data for MRTX849 support $926M follow-on as Mirati’s market cap crosses $10B

Mirati parlays MRTX849 data from EORTC-NCI-AACR into $926 million follow-on offering and a market cap of $10.5 billion. 

Oct 27, 2020 | 12:20 AM GMT

Mirati’s shares rose to an all-time high on Monday after the company dropped the latest response rate data in the closely-watched KRAS inhibitor race, but it’s still too early to tell how

Read the full 820 word article

How to gain access

Continue reading with a
two-week free trial.